June, 2017 | BMT Reviews, Multiple Myeloma
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
May, 2017 | Uncategorized
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
May, 2017 | Uncategorized
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Sergio A. Giralt, MD Program Chair Professor of Medicine Weill Cornell College of Medicine Chief Attending, Adult BMT Service Memorial...
May, 2017 | Uncategorized
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Stephan A. Grupp, MD, PhD Program Chair Director of the Cancer Immunotherapy Program Director of Translational Research for the Center...
May, 2017 | Webinars
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Stephan A. Grupp, MD, PhD Program Chair Director of the Cancer Immunotherapy Program Director of Translational Research for the Center...
April, 2017 | Infectious Disease, Lymphoma, MDS / Myeloproliferative, Multiple Myeloma, Webinars
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Sergio A. Giralt, MD Program Chair Professor of Medicine Weill Cornell College of Medicine Chief Attending, Adult BMT Service Memorial...
August, 2016 | Infectious Disease, Transplantation / Stem Cell, Webinars
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
July, 2016 | BMT Reviews, Lymphoma
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
June, 2016 | BMT Reviews, Multiple Myeloma
In this CME activity, leading experts in multiple myeloma will review changes in the treatment paradigm, optimal patient selection for transplant, and data from recent clinical trials. They will also provide insight into new strategies for individualized management, the role of early versus late transplant, and how to incorporate novel therapies into clinical practice.
May, 2016 | Multiple Myeloma, Webinars
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Chairs Kenneth C. Anderson, MD Kraft Family Professor of Medicine, Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center and...
